A Dose Escalation Study to Investigate the Safety, Pharmacokinetics (PK), Pharmacodynamics (PD), and Clinical Activity of GSK525762 Plus Trametinib in Subjects With Solid Tumors
WithdrawnNCT03266159
GlaxoSmithKlineSolid Tumours
Start: 2017-11-27End: 2020-08-19Updated: 2017-12-08